Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial

被引：48
|
作者：
Attard, Gerhardt [1 ,2 ,3 ]
Sydes, Matthew R. [4 ]
Mason, Malcolm D. [5 ]
Clarke, Noel W. [6 ]
Aebersold, Daniel [7 ]
de Bono, Johann S. [1 ,2 ,3 ]
Dearnaley, David P. [1 ,2 ,3 ]
Parker, Chris C. [1 ,2 ,3 ]
Ritchie, Alastair W. S. [4 ]
Russell, J. Martin [8 ]
Thalmann, George [9 ]
Cassoly, Estelle [10 ]
Millman, Robin
Matheson, David
Schiavone, Francesca [4 ]
Spears, Melissa R. [4 ]
Parmar, Mahesh K. B. [4 ]
James, Nicholas D. [11 ]
机构：
[1] Inst Canc Res, London SW3 6JB, England
[2] Royal Marsden NHS Fdn Trust, London, England
[3] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[4] UCL, MRC, Clin Trials Unit, London, England
[5] Cardiff Univ, Sch Med, Velindre Hosp, Cardiff CF10 3AX, S Glam, Wales
[6] Christie NHS Fdn Trust, Dept Urol, Manchester, Lancs, England
[7] Univ Bern, Bern, Switzerland
[8] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland
[9] Univ Hosp Bern, Dept Urol, CH-3010 Bern, Switzerland
[10] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland
[11] Univ Warwick, Warwick, England
来源：
EUROPEAN UROLOGY | 2014年 / 66卷 / 05期
关键词：
METASTATIC PROSTATE-CANCER; INCREASED SURVIVAL; INHIBITOR; RECEPTOR; ACETATE;
D O I：
10.1016/j.eururo.2014.05.038
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：799 / 802
页数：4
相关论文
共 50 条
  • [21] miRNAs and androgen deprivation therapy for prostate cancer
    Konoshenko, Maria Yu
    Bryzgunova, Olga E.
    Laktionov, Pavel P.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (02):
  • [22] Hematological changes during androgen deprivation therapy
    Grossmann, Mathis
    Zajac, Jeffrey D.
    ASIAN JOURNAL OF ANDROLOGY, 2012, 14 (02) : 187 - 192
  • [23] Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor
    Lazaro Quintela, Martin
    Leon Mateos, Luis
    Vazquez Estevez, Sergio
    Fernandez Calvo, Ovidio
    Anido Herranz, Urbano
    Afonso Afonso, Francisco Javier
    Santome, Lucia
    Anton Aparicio, Luis
    CANCER TREATMENT REVIEWS, 2015, 41 (03) : 247 - 253
  • [24] Androgen Deprivation Causes Epithelial-Mesenchymal Transition in the Prostate: Implications for Androgen-Deprivation Therapy
    Sun, Yuting
    Wang, Bu-Er
    Leong, Kevin G.
    Yue, Peng
    Li, Li
    Jhunjhunwala, Suchit
    Chen, Darrell
    Seo, Kyounghee
    Modrusan, Zora
    Gao, Wei-Qiang
    Settleman, Jeffrey
    Johnson, Leisa
    CANCER RESEARCH, 2012, 72 (02) : 527 - 536
  • [25] Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
    Izumi, Kouji
    Shima, Takashi
    Mita, Koji
    Kato, Yuki
    Kamiyama, Manabu
    Inoue, Shogo
    Tanaka, Nobumichi
    Hoshi, Seiji
    Okamura, Takehiko
    Yoshio, Yuko
    Enokida, Hideki
    Chikazawa, Ippei
    Kawai, Noriyasu
    Hashimoto, Kohei
    Fukagai, Takashi
    Shigehara, Kazuyoshi
    Takahara, Shizuko
    Kadono, Yoshifumi
    Mizokami, Atsushi
    EUROPEAN UROLOGY OPEN SCIENCE, 2022, 41 : 16 - 23
  • [26] Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer
    Shore, Neal
    Higano, Celestia S.
    George, Daniel J.
    Sternberg, Cora N.
    Saad, Fred
    Tombal, Bertrand
    Miller, Kurt
    Kalinovsky, Jan
    Jiao, XiaoLong
    Tangirala, Krishna
    Sartor, Oliver
    PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (04) : 680 - 688
  • [27] Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population
    Zhao, Hanson
    Howard, Lauren E.
    De Hoedt, Amanda M.
    Terris, Martha K.
    Amling, Christopher L.
    Kane, Christopher J.
    Cooperberg, Matthew R.
    Aronson, William J.
    Klaassen, Zachary
    Polascik, Thomas J.
    Vidal, Adriana C.
    Freedland, Stephen J.
    PROSTATE, 2021, 81 (07) : 390 - 397
  • [28] Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial
    Khalaf, Daniel J.
    Sunderland, Katherine
    Eigl, Bernhard J.
    Kollmannsberger, Christian K.
    Ivanov, Nikita
    Finch, Daygen L.
    Oja, Conrad
    Vergidis, Joanna
    Zulfiqar, Muhammad
    Gleave, Martin E.
    Chi, Kim N.
    EUROPEAN UROLOGY, 2019, 75 (06) : 940 - 947
  • [29] Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study
    Iguchi, Taro
    Kimura, Go
    Fukasawa, Satoshi
    Suzuki, Hiroyoshi
    Uemura, Hiroji
    Nishimura, Kazuo
    Matsumoto, Hiroaki
    Yokomizo, Akira
    Armstrong, Andrew J.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Kunieda, Futoshi
    Stenzl, Arnulf
    INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (07) : 765 - 773
  • [30] Androgen Glucuronidation: An Unexpected Target for Androgen Deprivation Therapy, with Prognosis and Diagnostic Implications
    Grosse, Laurent
    Paquet, Sophie
    Caron, Patrick
    Fazli, Ladan
    Rennie, Paul S.
    Belanger, Alain
    Barbier, Olivier
    CANCER RESEARCH, 2013, 73 (23) : 6963 - 6971
12345